12 Additional Pending Patent Applications Submitted for evo® Smart Shippers, Liquid Nitrogen Dry Vapor Shippers and Cold Chain SaaS Application
On March 26, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and SAVSU Technologies, the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, announced that the USPTO has issued a notice of allowance for a second patent application titled “Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials”. The inventors are Bruce McCormick, President of SAVSU Technologies, and Mike Rice, CEO of BioLife Solutions.
The patents will issue on April 10th, 2018, under patent numbers 9,939,422 and 9,939,423.
Since the formation of the BioLife Solutions – SAVSU Technologies joint venture in the fourth quarter of 2014, the companies have submitted 12 other patent applications related to novel innovations incorporated into current, or to be incorporated into future, precision thermal shipping containers under the evo brand, including models that precisely maintain biologic payload temperature stability across the entire shipping continuum including -196°C using liquid nitrogen dry vapor shippers, -80°C using dry ice, and 2° – 8°C and controlled room temperature (CRT) using conditioned phase change insulating materials. These patent applications also include claims related to the evo.is Cold Chain Software as a Service (SaaS) live cell visibility platform.
Bruce McCormick commented, “We are pleased to receive this second notice of allowance of what we believe will be a series of patent grants. We filed several applications to protect our growing intellectual property estate. We believe our hardware and software innovations, embodied in current and future evo models, will offer significant value to the growing regenerative and personalized medicine markets.”
Mike Rice, BioLife CEO, remarked, “This notice of allowance is another validation of the vision SAVSU and BioLife formed several years ago, with a focused and intentional goal to improve cold chain logistics of cell and gene therapies. We believe the advanced and innovative evo hardware and software technologies will have tremendous impact on the preservation, delivery, and quality management of these precious, time and temperature sensitive biologic medicines.”
SAVSU is a leading designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. For more information please visit www.savsu.com.